Regeneron Pharmaceuticals, Inc. (REGN) Analyst Ratings & Price Targets

Regeneron Pharmaceuticals, Inc.

REGN · NASDAQ-GS

Analyst Consensus

Buy

21 analysts

$770

Current

—

Low

$857

Average

—

High

Average target implies +11.25% versus the current price.

The ratings synthesis for REGN has not been generated yet.

Rating Actions

No individual rating actions have been captured for REGNyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BMO CAPITAL MKT

CANACCORD GENUI

CANTOR FITZGERA

DEUTSCHE BK SEC

GOLDMAN SACHS

GUGGENHEIM SEC.

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RBC CAPITAL

TD COWEN

TRUIST SECURITI

WELLS FARGO SEC

WESTPARK CAPITA

Symbol: REGN
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NASDAQ-GS

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ®, which produces optimized fully human antibodies and new classes of bispecific antibodies.

Analyst Consensus

See all

Buy